🇺🇸 FDA
Company

Atara

Atara Biotherapeutics

ATRA biotech USA

Quick answer

Atara is a biotech company (ATRA) headquartered in THOUSAND OAKS, CA, USA with 9 tracked pipeline programs.

Pipeline (9)

project

ATA188

Primary Progressive Multiple Sclerosis

Phase 2 · mab · terminated

1 trials project

CMV-pp65 CTLs

Cytomegalovirus

Phase 2 · mab · completed

1 trials project

EBV-specific T cells (EBV-CTLs)

EBV-induced Lymphomas

Phase 2 · mab · completed

1 trials project

Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

EBV-induced Lymphomas

Phase 2 · mab · completed

1 trials project

Tabelecleucel

Nasopharyngeal Carcinoma

Phase 2 · mab · terminated

1 trials project

ATA3219

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 · small_molecule · terminated

1 trials project

ATA3219

Lupus Nephritis

Phase 1 · small_molecule · terminated

1 trials project

WT1-sensitized T cells

Leukemia

Phase 1 · mab · completed

1 trials project

cyclophosphamide

Malignant Pleural Mesothelioma (MPM)

Phase 1 · small_molecule · active

1 trials

Patents (8)

patent

US 12383572

Administration of an anti-activin-a compound to a subject

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11925663

Methods of managing tumor flare in adoptive immunotherapy

Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11541070

Administration of an anti-activin-A compound to a subject

Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9968586

Mast cell stabilizers treatment for systemic disorders

Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9962363

Mast cell stabilizers treatment for systemic disorders

Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9707206

Mast cell stabilizers treatment for systemic disorders

Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9265749

Methods for the treatment of systemic disorders treatable with mast cell stabili

Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 8501678

Variant activin receptor polypeptides and uses thereof

Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)